Surgical & Medical Instruments & Apparatus
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy. It operates in two segments, Cardiovascular and Endoscopy. The company provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate strictures; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
Sector
Discounted Cash Flow Valuation of Merit Medical Systems Inc
Growth
%
%
Discount
%
%
Multiple
g\r | +10% | +11% | +12% | +13% | +14% |
---|---|---|---|---|---|
0% | 10 | 9 | 8 | 8 | 7 |
+1% | 11 | 10 | 9 | 8 | 8 |
+2% | 13 | 11 | 10 | 9 | 8 |
+3% | 14 | 13 | 11 | 10 | 9 |
+4% | 17 | 14 | 12 | 11 | 10 |
Years | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | TV |
---|---|---|---|---|---|---|---|---|---|---|---|---|
FCF | $133.6M | $173.7M | $221M | $275M | $334.6M | $397.8M | $461.9M | $523.5M | $578.8M | $623.8M | $655M | $6.55B |
DCF | $151.1M | $167.1M | $180.8M | $191.3M | $197.8M | $199.7M | $196.8M | $189.2M | $177.3M | $161.9M | $1.619B | |
Value | $3.432B |
In the chart Earnings are multiplied by this value.
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Net Margin | 4.4% | 3.3% | 3.8% | 4.8% | 0.55% | -1% | 4.5% | 6.5% | 7.5% | 7.9% |
ROA | 4.8% | 3.7% | 3.9% | 3.7% | 0.88% | -0.094% | 3.7% | 5.3% | 5.3% | 5.7% |
ROE | 5.1% | 4% | 4.1% | 4.5% | 0.57% | -1% | 4.7% | 6.5% | 7.9% | 8.2% |
The average Net Margin over the past 5 years is +3.8%.
The trend of Net Margin over the past 5 years is +1.06%.
The average ROA over the past 5 years is +3.13%.
The trend of ROA over the past 5 years is +0.72%.
The average ROE over the past 5 years is +3.85%.
The trend of ROE over the past 5 years is +1.15%.
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Debt FCF | 11.76 | 16.14 | 12.38 | 17.99 | -1243.06 | 3.01 | 2.11 | 3.02 | 7.64 | 6.15 |
Debt Equity | 0.47 | 0.67 | 0.44 | 0.45 | 0.47 | 0.37 | 0.24 | 0.18 | 0.70 | 0.66 |
MIN | ||||||||||
Graham Stability | - | - | 100% | 100% | 18% | -39% | 100% | 100% | 100% | -39% |
The Debt/FCF trailing twelve month is 6.15.
The trend of Debt/FCF over the past 5 years is 105.30.
Graham’s Stability measure stands at -0.39.
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
---|---|---|---|---|---|
Revenue | 11% | 7.3% | 9.3% | 9.2% | -0.73% |
Net Income | 25% | 18% | - | 27% | 3.8% |
Stockholders Equity | 13% | 5.2% | 7.8% | 5% | -1.5% |
FCF | 27% | 37% | -2.4% | 60% | 1.2% |
The Revenue CAGR over the past 5 years is +7.33%.
The trend of Revenue growth rate over the past 5 years is -0.73%.
The Earnings CAGR over the past 5 years is +17.58%.
The trend of Earnings growth rate over the past 5 years is +3.8%.
The Equity CAGR over the past 5 years is +5.2%.
The trend of Equity growth rate over the past 5 years is -1.5%.
The FCF CAGR over the past 5 years is +36.72%.
The trend of FCF growth rate over the past 5 years is +1.16%.